WO2001044270A3 - Methods for treating and preventing diabetic complications by use of angiotensin-related peptides - Google Patents

Methods for treating and preventing diabetic complications by use of angiotensin-related peptides Download PDF

Info

Publication number
WO2001044270A3
WO2001044270A3 PCT/US2000/032133 US0032133W WO0144270A3 WO 2001044270 A3 WO2001044270 A3 WO 2001044270A3 US 0032133 W US0032133 W US 0032133W WO 0144270 A3 WO0144270 A3 WO 0144270A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
diabetic complications
treating
analogues
methods
Prior art date
Application number
PCT/US2000/032133
Other languages
French (fr)
Other versions
WO2001044270A2 (en
Inventor
Kathleen E Rodgers
Gere S Dizerega
Original Assignee
Univ Southern California
Kathleen E Rodgers
Gere S Dizerega
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California, Kathleen E Rodgers, Gere S Dizerega filed Critical Univ Southern California
Priority to AU17929/01A priority Critical patent/AU1792901A/en
Publication of WO2001044270A2 publication Critical patent/WO2001044270A2/en
Publication of WO2001044270A3 publication Critical patent/WO2001044270A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides improved methods, kits, and pharmaceutical compositions for treating or preventing diabetic complications by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII) analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to treat or prevent diabetic complications.
PCT/US2000/032133 1999-12-16 2000-11-27 Methods for treating and preventing diabetic complications by use of angiotensin-related peptides WO2001044270A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17929/01A AU1792901A (en) 1999-12-16 2000-11-27 Methods for treating and preventing diabetic complications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17236699P 1999-12-16 1999-12-16
US60/172,366 1999-12-16

Publications (2)

Publication Number Publication Date
WO2001044270A2 WO2001044270A2 (en) 2001-06-21
WO2001044270A3 true WO2001044270A3 (en) 2002-10-31

Family

ID=22627420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032133 WO2001044270A2 (en) 1999-12-16 2000-11-27 Methods for treating and preventing diabetic complications by use of angiotensin-related peptides

Country Status (2)

Country Link
AU (1) AU1792901A (en)
WO (1) WO2001044270A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0105509B8 (en) * 2001-11-05 2021-05-25 Univ Minas Gerais formulations of the angiotensin- (1-7) peptide using cyclodextrins, liposomes and the plga polymer
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
PT2536422E (en) 2011-02-02 2014-07-18 Univ Southern California Methods for treating diabetic foot ulcers
US8557958B1 (en) * 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014858A1 (en) * 1994-11-14 1996-05-23 University Of Southern California Use of angiotensin ii fragments and analogs thereof in tissue repair

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014858A1 (en) * 1994-11-14 1996-05-23 University Of Southern California Use of angiotensin ii fragments and analogs thereof in tissue repair

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF KIDNEY DISEASES, (1999 NOV) 34 (5) 818-23. *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FIORETTO P ET AL: "IMPAIRED RESPONSE TO ANGIOTENSIN II IN TYPE 1 INSULIN-DEPENDENT DIABETES MELLITUS ROLE OF PROSTAGLANDINS AND SODIUM LITHIUM COUNTERTRANSPORT ACTIVITY.", XP002172267, retrieved from STN Database accession no. 1991:476897 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VALLON, VOLKER ET AL: "Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction", XP002172266, retrieved from STN Database accession no. 123:30691 CA *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; FERRARIO C M ET AL: "Counterregulatory actions of angiotensin-(1-7).", XP002172269, retrieved from STN Database accession no. 97462751 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; FERRARIO C M ET AL: "Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis.", XP002172270, retrieved from STN Database accession no. 1998394364 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; SHARMA K ET AL: "Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependen diabetic patients.", XP002172268, retrieved from STN Database accession no. 2000030192 *
DIABETOLOGIA, (1991) 34 (8), 595-603. *
HYPERTENSION, (1997 SEP) 30 (3 PT 2) 535-41. REF: 63 *
J. AM. SOC. NEPHROL. (1995), 5(10), 1761-7, 1995 *
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (1998 SEP) 9 (9) 1716-22. REF: 73 *

Also Published As

Publication number Publication date
AU1792901A (en) 2001-06-25
WO2001044270A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
WO2002053177A3 (en) Agents and methods for treating pain
GT199700009AA (en) COMBINED THERAPY FOR OSTEOPOROSIS
MXPA02007117A (en) Compositions for delivery of a cortisol antagonist.
WO2000053211A3 (en) Method of promoting myocyte proliferation and myocardial tissue repair
WO2002047715A3 (en) Compositions of peptide crystals
BRPI0411319A (en) therapeutically active compounds and their use
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
DE69924715D1 (en) USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING OVERLAPPING OF WHITE BLOOD CELLS AND MOBILIZING HAEMATOPOIETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO1998033813A3 (en) Method for accelerating healing of thermal injuries
WO2003035679A3 (en) Molecules
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
TW200503689A (en) Pharmaceutical compositions of atorvastatin
CA2323237A1 (en) Improved radiation therapy methods
WO2005020970A3 (en) Protease inhibitor compositions for prevention and treatment of skin conditions
ATE335496T1 (en) ANGIOTENSIN II AND ANALOGUES FOR LIMITING SCARS AND ADHESION FORMATION
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MX9601151A (en) Use of calcitonin gene derived peptide antagonist for the treatment of lichens and pruritus and composition obtained therefrom.
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2002006308A3 (en) Methods for promoting dendritic cell proliferation or differentiation
WO1999047150A3 (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP